Genentech and Seattle Genetics Collaborate for SGN-40
Genentech (San Francisco, CA, www.genentech.com) and Seattle Genetics, Inc. (Bothell, WA, www.seattlegenetics.com) have signed an exclusive worldwide license agreement to develop and commercialize SGN-40.
Genentech (San Francisco, CA, www.genentech.com) and Seattle Genetics, Inc. (Bothell, WA, www.seattlegenetics.com) have signed an exclusive worldwide license agreement to develop and commercialize SGN-40. SGN-40 is a humanized MAb currently in Phase 1 and Phase 2 clinical trials for multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma.
Under the terms of the agreement, Seattle Genetics will receive an upfront payment of $60 million and potential milestone payments exceeding $800 million. The milestone payments, which are dependent on clinical and regulatory events across multiple disease indications worldwide, as well as attainment of certain annual net sales levels, include $20 million in committed payments during the first two years of the agreement.
Genentech will fund future research, development, manufacturing, and commercialization costs. Seattle Genetics will continue certain clinical trials and development activities, the costs of which will be reimbursed by Genentech. Seattle Genetics also has an option for copromotion rights on SGN-40 in the US.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
